Review



mass spectrometry-based mutation profiling assay  (Sequenom)

 
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Sequenom mass spectrometry-based mutation profiling assay
    Mass Spectrometry Based Mutation Profiling Assay, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mutation+profiling/mass+spectrometry+array+mutation+profiling+massarray+system/pmc05691362-110-15-20
    Average 90 stars, based on 1 article reviews
    mass spectrometry-based mutation profiling assay - by Bioz Stars, 2026-11
    90/100 stars

    Images

    Related Articles

    other:

    Article Title: Erlotinib versus Radiation Therapy for Brain Metastases in Patients with EGFR -Mutant Lung Adenocarcinoma
    Article Snippet: Beginning in January 2009, 92 specific point mutations in multiple genes were identified using a mass spectrometry-based mutation profiling assay (Sequenom, San Diego, CA) [ 18 ].

    Article Title: Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
    Article Snippet: Beginning in January 2009, a mass spectrometry–based mutation profiling assay (Sequenom) was used on all samples.

    Article Title: Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry.
    Article Snippet: 0002-9610/$ see front matter 2013 http://dx.doi.org/10.1016/j.amjsurg.20 Abstract BACKGROUND: Determining the molecular profile of colon and rectal cancers offers the possibility of personalized cancer treatment.. The purpose of this study was to determine whether known genetic mutations associated with colorectal carcinogenesis differ between colon and rectal cancers and whether they are associated with survival.. METHODS: The Oregon Colorectal Cancer Registry is a prospectively maintained, institutional review board–approved tissue repository with associated demographic and clinical information.

    Article Title: Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR TKI therapy in 155 patients with EGFR mutant Lung Cancers
    Article Snippet: Beginning in January 2009, a mass spectrometry-based mutation profiling assay (Sequenom), was used on all samples.

    Article Title: Patterns of Initial and Intracranial Failure in Metastatic EGFR-mutant Non-Small Cell Lung Cancer Treated with Erlotinib
    Article Snippet: Beginning in January 2009, 92 specific point mutations in multiple genes were identified by use of a mass spectrometry–based mutation profiling assay (Sequenom, San Diego, CA).

    Article Title: Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas
    Article Snippet: Determination of IDH-Mutation Status IDH mutations were determined using immunohistochemistry, 14 , 15 mass spectrometry–based mutation genotyping (OncoMap, Sequenom), 15 , 16 or multiplex exome sequencing (OncoPanel, Illumina), 17 , 18 depending on which genotyping technologies were available at the time of diagnosis.

    DNA Extraction:

    Article Title: Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas
    Article Snippet: .. In the nine cases in which DNA extraction was achieved (six cerebellar and three brainstem tumors), mass spectrometry array mutation profiling (MassARRAY system, Sequenom, San Diego, CA) or fluorescence melting curve PCR analysis [ 7 ] confirmed the absence of R132H IDH1 mutation. .. In the nine cases in which DNA extraction was achieved (six cerebellar and three brainstem tumors), mass spectrometry array mutation profiling (MassARRAY system, Sequenom, San Diego, CA) or fluorescence melting curve PCR analysis [ 7 ] confirmed the absence of R132H IDH1 mutation.

    Mass Spectrometry:

    Article Title: Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas
    Article Snippet: .. In the nine cases in which DNA extraction was achieved (six cerebellar and three brainstem tumors), mass spectrometry array mutation profiling (MassARRAY system, Sequenom, San Diego, CA) or fluorescence melting curve PCR analysis [ 7 ] confirmed the absence of R132H IDH1 mutation. .. In the nine cases in which DNA extraction was achieved (six cerebellar and three brainstem tumors), mass spectrometry array mutation profiling (MassARRAY system, Sequenom, San Diego, CA) or fluorescence melting curve PCR analysis [ 7 ] confirmed the absence of R132H IDH1 mutation.

    Mutagenesis:

    Article Title: Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas
    Article Snippet: .. In the nine cases in which DNA extraction was achieved (six cerebellar and three brainstem tumors), mass spectrometry array mutation profiling (MassARRAY system, Sequenom, San Diego, CA) or fluorescence melting curve PCR analysis [ 7 ] confirmed the absence of R132H IDH1 mutation. .. In the nine cases in which DNA extraction was achieved (six cerebellar and three brainstem tumors), mass spectrometry array mutation profiling (MassARRAY system, Sequenom, San Diego, CA) or fluorescence melting curve PCR analysis [ 7 ] confirmed the absence of R132H IDH1 mutation.

    Fluorescence:

    Article Title: Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas
    Article Snippet: .. In the nine cases in which DNA extraction was achieved (six cerebellar and three brainstem tumors), mass spectrometry array mutation profiling (MassARRAY system, Sequenom, San Diego, CA) or fluorescence melting curve PCR analysis [ 7 ] confirmed the absence of R132H IDH1 mutation. .. In the nine cases in which DNA extraction was achieved (six cerebellar and three brainstem tumors), mass spectrometry array mutation profiling (MassARRAY system, Sequenom, San Diego, CA) or fluorescence melting curve PCR analysis [ 7 ] confirmed the absence of R132H IDH1 mutation.

    Polymerase Chain Reaction:

    Article Title: Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas
    Article Snippet: .. In the nine cases in which DNA extraction was achieved (six cerebellar and three brainstem tumors), mass spectrometry array mutation profiling (MassARRAY system, Sequenom, San Diego, CA) or fluorescence melting curve PCR analysis [ 7 ] confirmed the absence of R132H IDH1 mutation. .. In the nine cases in which DNA extraction was achieved (six cerebellar and three brainstem tumors), mass spectrometry array mutation profiling (MassARRAY system, Sequenom, San Diego, CA) or fluorescence melting curve PCR analysis [ 7 ] confirmed the absence of R132H IDH1 mutation.



    Similar Products

    86
    Caris Life Sciences tumor mutational profiles
    (A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
    Tumor Mutational Profiles, supplied by Caris Life Sciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mutation+profiling/comprehensive+molecular+profiling/pmc12420367-92-2-16
    Average 86 stars, based on 1 article reviews
    tumor mutational profiles - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    90
    Broad Institute Inc human cancer cell line expression profiles and somatic mutation data
    (A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
    Human Cancer Cell Line Expression Profiles And Somatic Mutation Data, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mutation+profiling/transcriptional+profiling+of+human+cancer+cell+lines/pm40595395-261-21-35
    Average 90 stars, based on 1 article reviews
    human cancer cell line expression profiles and somatic mutation data - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Illumina Inc somatic mutation profiles
    (A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
    Somatic Mutation Profiles, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mutation+profiling/somatic+mutation+profiles/pm40435135-1-29-19
    Average 90 stars, based on 1 article reviews
    somatic mutation profiles - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    99
    Bio-Rad oncocompasstm target cancer mutation profiling liquid kit burning rock biotech n a ddpcrtm supermix for probes
    (A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
    Oncocompasstm Target Cancer Mutation Profiling Liquid Kit Burning Rock Biotech N A Ddpcrtm Supermix For Probes, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mutation+profiling/Droplet+PCR+Supermix/pmc12147912__mmc2-421-104-121
    Average 99 stars, based on 1 article reviews
    oncocompasstm target cancer mutation profiling liquid kit burning rock biotech n a ddpcrtm supermix for probes - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    95
    Zymo Research mutational profiling map fragmentation buffer
    (A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
    Mutational Profiling Map Fragmentation Buffer, supplied by Zymo Research, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mutation+profiling/Digestion+Buffer/pmc12000875-61-8-54
    Average 95 stars, based on 1 article reviews
    mutational profiling map fragmentation buffer - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    90
    Broad Institute Inc somatic mutation data and expression profile data of human cancer cell lines (ccls)
    (A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
    Somatic Mutation Data And Expression Profile Data Of Human Cancer Cell Lines (Ccls), supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mutation+profiling/transcriptional+profiling+of+human+cancer+cell+lines/pmc11362543-138-10-23
    Average 90 stars, based on 1 article reviews
    somatic mutation data and expression profile data of human cancer cell lines (ccls) - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Seegene Technologies rt-pcr detecting specific spike mutation profiles allplex sars-cov-2 variants i assay
    (A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
    Rt Pcr Detecting Specific Spike Mutation Profiles Allplex Sars Cov 2 Variants I Assay, supplied by Seegene Technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mutation+profiling/allplex+sars+cov+2+assay/pm38570699-51-23-34
    Average 90 stars, based on 1 article reviews
    rt-pcr detecting specific spike mutation profiles allplex sars-cov-2 variants i assay - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    BioResource International Inc mutation profiles
    (A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
    Mutation Profiles, supplied by BioResource International Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mutation+profiling/mutation+profiles/pm38639832-24-37-17
    Average 90 stars, based on 1 article reviews
    mutation profiles - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Broad Institute Inc tcga mutation profiles
    (A) <t>Mutational</t> frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).
    Tcga Mutation Profiles, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mutation+profiling/tcga+mutation+profiles/pmc10980029__media___1-231-6-14
    Average 90 stars, based on 1 article reviews
    tcga mutation profiles - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    Image Search Results


    (A) Mutational frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).

    Journal: Cancer Medicine

    Article Title: Actionable Genes and Carcinogenic Pathways for Gastric Cancer in Latinos

    doi: 10.1002/cam4.71216

    Figure Lengend Snippet: (A) Mutational frequencies of the top mutated genes identified in the 72 non‐hypermutated gastric cancer (GC) tumors from PRH ( n = 72 for all genes except ARID1A ( n = 62), KMT2D ( n = 70), MYH11 ( n = 63), IRS2 ( n = 65), and CLTCL1 ( n = 61)). (B) Mutational frequencies by anatomical location of non‐hypermutated GC tumors from PRH. For Fundus/Cardia, there were 13 cases, and n = 13 for all genes, except for MYH11 , PHOX2B , and PER1 , which had n = 12. For the Body, there were 45 cases, and all genes had n = 45, except for ARID1A ( n = 38), KMT2D ( n = 43), and CACNA1D ( n = 39). For the Antrum, there were 14 cases, and all genes had n = 14, except for NOTCH1 ( n = 12), CDKN2A ( n = 13), and NFE2L2 ( n = 13).

    Article Snippet: We examined tumor mutational profiles of GC from 106 PRH between 2015 and 2022 (provided by CARIS Life Sciences and the Precision Oncology Alliance).

    Techniques:

    Frequency of genetic alterations in key signaling pathways in non‐hypermutated gastric cancer cases leading to deregulation of the WNT/β‐catenin, MAPK, PI3K, TGF‐β, and p53 signaling pathways in the non‐hypermutated cases. The frequencies of alterations are expressed as a percentage of all cases. The red color denotes the overall mutational frequency, and blue denotes the amplification frequency for each gene. Figure adapted from: Nature, volume 487, pages 330–337 (2012).

    Journal: Cancer Medicine

    Article Title: Actionable Genes and Carcinogenic Pathways for Gastric Cancer in Latinos

    doi: 10.1002/cam4.71216

    Figure Lengend Snippet: Frequency of genetic alterations in key signaling pathways in non‐hypermutated gastric cancer cases leading to deregulation of the WNT/β‐catenin, MAPK, PI3K, TGF‐β, and p53 signaling pathways in the non‐hypermutated cases. The frequencies of alterations are expressed as a percentage of all cases. The red color denotes the overall mutational frequency, and blue denotes the amplification frequency for each gene. Figure adapted from: Nature, volume 487, pages 330–337 (2012).

    Article Snippet: We examined tumor mutational profiles of GC from 106 PRH between 2015 and 2022 (provided by CARIS Life Sciences and the Precision Oncology Alliance).

    Techniques: Protein-Protein interactions, Amplification